NCT02128126View on ClinicalTrials.gov

Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Cervical Cancer
Interventions
DRUG

ISA101/ISA101b

Four dose levels ISA101/ISA101b

Trial Locations (15)

1180

Chirec Cancer Institute, Brussels

2650

UZA, Antwerp

3000

UZL, Leuven

30625

Medizinische Hochschule Hannover - Klinik für Frauenheilkunde, Hanover

40225

Universitätsklinikum Düsseldorf - Frauenklinik, Düsseldorf

45147

Universitätsklinikum Essen - Klinik für Frauenheilkunde, Essen

69120

Universitätsklinikum Heidelberg, Heidelberg

B-9000

UZG, Ghent

B-4000

CHU of Liege Site Citadelle, Liège

1066 CX

NKI/AVL, Amsterdam

1105 AZ

AMC, Amsterdam

9713 GZ

UMCG, Groningen

2333 ZA

LUMC, Leiden

6229 HX

MUMC, Maastricht

6525 GA

Radboud UMC, Nijmegen

Sponsors
All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

ISA Pharmaceuticals

INDUSTRY

NCT02128126 - Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter